Skip to main content
. 2014 Aug 17;2014:704207. doi: 10.1155/2014/704207

Table 1.

Model features.

Patients 50,000

Maximum treatment period with belimumab 10 years

Maximum effect related to belimumab Lifetime

Subgroup Patient with low complement and anti-dsDNA

Responder rule Reduction SELENA-SLEDAI ≥ 4 at 24th week

Natural history model JH-AMS∗ forced in, involvement removed

Long term disease activity model Adjusted natural history models (NHM)

One-year steroid model NHM

∗Johns Hopkins University (JH) Adjusted Mean SLEDAI (AMS).